Vaxcyte (PCVX) Retained Earnings (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Retained Earnings data on file, last reported at -$2.5 billion in Q1 2026.

• On a quarterly basis, Retained Earnings fell 61.9% year-over-year to -$2.5 billion in Q1 2026; TTM through Mar 2026 was -$2.5 billion, a 61.9% decrease from a year earlier, with the FY2025 full-year figure at -$2.2 billion, down 55540.25% from the prior year.
• Retained Earnings for Q1 2026 stood at -$2.5 billion, down from -$2.2 billion in the prior quarter.
• Over the last five years, Retained Earnings for PCVX reached as high as $2.9 million in Q1 2024 and fell as low as -$2.5 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$579.9 million across 5 years, with a median of -$3.9 million in 2024.
• Across the five-year window, Retained Earnings plunged 255964.27% in 2023 and surged 515.83% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$361000.0 in 2022, then plunged by 255964.27% to -$924.4 million in 2023, then soared by 99.58% to -$3.9 million in 2024, then sank by 55540.25% to -$2.2 billion in 2025, then dropped by 14.88% to -$2.5 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$2.5 billion in Q1 2026, -$2.2 billion in Q4 2025, and $856000.0 in Q3 2025.